UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2008
RAPTOR PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Delaware | 000-50720 | 98-0379351 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
9 Commercial Blvd., Suite 200, Novato, California 94949 | ||
(Address of principal executive offices and Zip Code) | ||
| ||
Registrant’s telephone number, including area code: (415) 382-8111 | ||
| ||
Not applicable | ||
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On November 6, 2008, Raptor Pharmaceuticals Corp. (the “Company”) issued a press release announcing an update regarding its preclinical program which utilizes drug-targeting platforms derived from the human receptor-associated protein (“RAP”) and related proteins. The Company signed a collaborative research agreement with the Brigham and Women’s Hospital involving the characterization of certain modified RAP proteins. The Company has also announced today a patent issuance in Japan relating to the NeuroTrans™ program.
The press release, in the form attached to this Current Report on Form 8-K as Exhibit 99.1, is incorporated by reference into this Item 8.01 in its entirety.
On November 4, 2008, the Company’s wholly-owned subsidiary, Bennu Pharmaceuticals Inc. amended Article I of its Certificate of Incorporation solely to change its corporate name from “Bennu Pharmaceuticals Inc.” to “Raptor Therapeutics Inc.”
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits |
|
|
99.1 |
| Press Release of the Company dated November 6, 2008. |
|
|
|
SIGNATURES |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
| RAPTOR PHARMACEUTICALS CORP. |
|
|
| |
|
|
| Kim R. Tsuchimoto |
Exhibit Index
Exhibit No. |
| Description |
99.1 |
| Press Release of the Company dated November 6, 2008. |
|
|
|